Based: Rockville, MD
Stock symbol: MGNX
Range: $14 to $16
IPO price: $16
Close Oct. 17: $25.17
Change: Up 57%
Raised: $80 million

The scoop: MacroGenics only recently made its public debut, so the honeymoon period with investors is still in its earliest stages. Shares shot up 50% on the first day of trading, renewing the hope for some that the IPO window will remain open while highlighting fears of a bubble in other quarters. MacroGenics plans to spend $50 million of its IPO haul on its lead program for margetuximab, a Phase II monoclonal antibody the company believes can treat HER2-positive breast cancer. MacroGenics has another $20 million earmarked for MGA271, a Phase I immunotherapy that targets the B7-H3 regulator, which is overexpressed in a variety of solid tumors, the company said. For a company that has faced real travails in the past, the IPO win helps demonstrate that a company can overcome adversity. It will need to produce solid pivotal results to justify the stock gains, though. MacroGenics is a 2013 Fierce 15 company.

For more:
Special Report:
2013 Fierce 15 - Macrogenics
MacroGenics shares soar on glittering $80M IPO debut
MacroGenics upsizes IPO offering in bid for $92M windfall
MacroGenics trumpets cancer immunotherapies in $60M IPO pitch
On a roll, MacroGenics scoops up $10M on tumor drug milestone


Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.